Inhibitory/suppressive oligodeoxynucleotide nanocapsules as simple oral delivery devices for preventing atopic dermatitis in mice

Yeqin Wang, Yoshinari Yamamoto, Suguru Shigemori, Takafumi Watanabe, Kazushi Oshiro, Xinyu Wang, Pengfei Wang, Takashi Sato, Shinichi Yonekura, Sachi Tanaka, Haruki Kitazawa, Takeshi Shimosato

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)

Abstract

Here, we report a simple and low-cost oral oligodeoxynucleotide (ODN) delivery system targeted to the gut Peyer's patches (PPs). This system requires only Dulbecco's modified eagle's medium, calcium chloride, ODNs, and basic laboratory equipment. ODN nanocapsules (ODNcaps) were directly delivered to the PPs through oral administration and were taken up by macrophages in the PPs, where they induced an immune response. Long-term continuous oral dosing with inhibitory/suppressive ODNcaps (iODNcaps, "iSG3caps" in this study) was evaluated using an atopic dermatitis mouse model to visually monitor disease course. Administration of iSG3caps improved skin lesions and decreased epidermal thickness. Underlying this effect is the ability of iSG3 to bind to and prevent phosphorylation of signal transducer and activator of transcription 6, thereby blocking the interleukin-4 signaling cascade mediated by binding of allergens to type 2 helper T cells. The results of our iSG3cap oral delivery experiments suggest that iSG3 may be useful for treating allergic diseases.

Original languageEnglish
Pages (from-to)297-309
Number of pages13
JournalMolecular Therapy
Volume23
Issue number2
DOIs
Publication statusPublished - 2015 Feb 3

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Inhibitory/suppressive oligodeoxynucleotide nanocapsules as simple oral delivery devices for preventing atopic dermatitis in mice'. Together they form a unique fingerprint.

Cite this